Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516199 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Electronic (PDF)Add to Basket
Site LicenseAdd to Basket
1 - 5 UsersAdd to Basket
CD ROMAdd to Basket
EnterprisewideAdd to Basket
Live Chat Live Help Software for Website

Hospira Partnering 2005-2012

CurrentPartnering, May 2012, Pages: 100


  Description  
   Table of Contents   
   Summary   
    
    
     
  Enquire before Buying   
  Send to a Friend   

This report provides all the information you require to better understand Hospira and its partnering interests and activities over the past five years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.

Benefits:


Partnering Agreements with Hospira report provides the user with the following key benefits:

Detailed company profile of the company
Partnering interests and therapy focus revealed
Partnering activity since 2005 – number of deals per year
Partnering activity for 2005-present
Activity by deal type
Activity by phase of development
Activity by therapeutic area
List of recent partner companies
Detailed listing of all partnering deals since 2005
Comprehensive access to actual contracts entered into by the company and its partners*
Insight into the terms included in a partnering agreement
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
*Subject to being published via regulatory requirements of the Securities Exchange Commission.




Customers who bought this item also bought

Partnering Agreements with Actavis

Partnering Agreements with Hospira

Merck KGaA / Merck Serono Partnering 2005-2012

Warner Chilcott Partnering 2005-2012

Genentech Partnering 2005-2012

Takeda Partnering 2005-2012

Mitsubishi Tanabe Partnering 2005-2012

Apotex Partnering 2005-2012

Kyowa Hakko Partnering 2005-2012

Shionogi Partnering 2005-2012



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds